Clinical Trial Update: Efficacy and Tolerability of Anacetrapib Added to Ongoing Lipid-Lowering Therapy in Adult Participants With Homozygous Familial Hypercholesterolemia (HoFH) (MK-0859-042) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating the efficacy and tolerability of adding anacetrapib to ongoing lipid-lowering therapy in adults with Homozygous Familial Hypercholester…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Homozygous Familial Hypercholesterolemia
• Hyperlipoproteinemia Type Ii

Drugs mentioned

• Anacetrapib (anacetrapib)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Hyperlipoproteinemia Type II, Homozygous Familial Hypercholesterolemia | Phase 3 | Status: TERMINATED